New hope for lung cancer patients when standard treatments fail

NCT ID NCT03334617

Summary

This study is testing several different drug combinations for people with advanced non-small cell lung cancer whose cancer has continued to grow despite receiving standard immunotherapy. The trial aims to find new treatment options for this group of patients who currently have limited choices. Researchers will match patients to different drug groups based on specific features of their cancer to see which approaches are most effective and safe.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NON-SMALL CELL LUNG CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Research Site

    Duarte, California, 91010, United States

  • Research Site

    Fullerton, California, 92835, United States

  • Research Site

    La Jolla, California, 92093, United States

  • Research Site

    Los Angeles, California, 90095, United States

  • Research Site

    Washington D.C., District of Columbia, 20016, United States

  • Research Site

    Chicago, Illinois, 60637, United States

  • Research Site

    Baltimore, Maryland, 21224, United States

  • Research Site

    Baltimore, Maryland, 21287, United States

  • Research Site

    Boston, Massachusetts, 02215, United States

  • Research Site

    St Louis, Missouri, 63110, United States

  • Research Site

    New York, New York, 10032, United States

  • Research Site

    Philadelphia, Pennsylvania, 19111, United States

  • Research Site

    Pittsburgh, Pennsylvania, 15232, United States

  • Research Site

    Nashville, Tennessee, 37203, United States

  • Research Site

    Nashville, Tennessee, 37212, United States

  • Research Site

    Houston, Texas, 77030, United States

  • Research Site

    Fairfax, Virginia, 22031, United States

  • Research Site

    Innsbruck, 6020, Austria

  • Research Site

    Salzburg, 5020, Austria

  • Research Site

    Vienna, 1140, Austria

  • Research Site

    Vienna, 1210, Austria

  • Research Site

    Edmonton, Alberta, T6G 1Z2, Canada

  • Research Site

    Brampton, Ontario, L6R 3J7, Canada

  • Research Site

    Ottawa, Ontario, K1H 8L6, Canada

  • Research Site

    Toronto, Ontario, M5G 2M9, Canada

  • Research Site

    Montreal, Quebec, H2X 3E4, Canada

  • Research Site

    Bordeaux, 33076, France

  • Research Site

    Nantes, 44093, France

  • Research Site

    Paris, 75877, France

  • Research Site

    Villejuif, 94800, France

  • Research Site

    Berlin, 12203, Germany

  • Research Site

    Esslingen a.N., 73730, Germany

  • Research Site

    Großhansdorf, 22927, Germany

  • Research Site

    Heidelberg, 69126, Germany

  • Research Site

    Haifa, 31096, Israel

  • Research Site

    Kfar Saba, 95847, Israel

  • Research Site

    Petah Tikva, 49100, Israel

  • Research Site

    Ramat Gan, 5265601, Israel

  • Research Site

    Seoul, 03080, South Korea

  • Research Site

    Seoul, 05505, South Korea

  • Research Site

    Seoul, 6351, South Korea

  • Research Site

    Barcelona, 08036, Spain

  • Research Site

    Madrid, 28007, Spain

  • Research Site

    Madrid, 28034, Spain

  • Research Site

    Seville, 41009, Spain

Conditions

Explore the condition pages connected to this study.